SuperworthAmneal Pharmaceuticals profit margin AMRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- 5.0%
- Operating margin, 12 months
- 14.6%
- Net margin on a year earlier
- +4.9 pts
- Peer median
- 18.1%
Over the twelve months to Jun 30, 2026, Amneal Pharmaceuticals kept 5.0% of its revenue as net profit, with an operating margin of 14.6% and a gross margin of 39.3%.
Five years earlier its net margin was 0.4%.
The median for 10 large drugmakers of a similar size is 18.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 2.4% | 13.1% | 36.9% |
| FY2024 | −4.2% | 8.9% | 36.5% |
| FY2023 | −3.5% | 8.5% | 34.3% |
| FY2022 | −5.9% | −4.3% | 35.5% |
| FY2021 | 0.5% | 7.3% | 36.7% |
| FY2020 | 4.6% | 4.6% | 31.5% |
| FY2019 | −22.3% | −15.3% | 21.7% |
| FY2018 | 1.9% | −1.2% | 43.1% |
| FY2017 | 0.0% | 23.7% | 50.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 5.0% | +4.9 pts | 14.6% | |
| Q1 FY26 | 4.0% | +4.5 pts | 14.3% | |
| Q4 FY25 | 2.4% | +6.6 pts | 13.1% | |
| Q3 FY25 | 0.2% | +7.1 pts | 12.2% | |
| Q2 FY25 | 0.1% | +6.8 pts | 13.2% | |
| Q1 FY25 | −0.5% | +6.3 pts | 12.7% | |
| Q4 FY24 | −4.2% | −0.7 pts | 8.9% | |
| Q3 FY24 | −6.9% | −7.3 pts | 7.0% | |
| Q2 FY24 | −6.7% | −6.6 pts | 6.7% | |
| Q1 FY24 | −6.8% | −0.8 pts | 6.4% | |
| Q4 FY23 | −3.5% | +2.3 pts | 8.5% | |
| Q3 FY23 | 0.4% | +6.6 pts | 9.5% |
Against its peers
Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| AMRXAmneal Pharmaceuticals | 5.0% |
| LGNDLigand Pharmaceuticals | 67.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| ALKSAlkermes plc. | 4.0% |
| TGTXTG Therapeutics | 55.2% |
| PTGXProtagonist Therapeutics | 29.4% |
| CORTCorcept Therapeutics | 6.6% |
| INDVIndivior Pharmaceuticals | 26.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| BMRNBiomarin Pharmaceutical | 2.1% |
| LQDALiquidia | 30.7% |
| Peer median | 18.1% |
Where Amneal Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Amneal Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.